Previous 10 | Next 10 |
home / stock / capr / capr articles
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and ex...
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exo...
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transfor...
Anthony Bergmann, Chief Financial Officer at Capricor Therapeutics (NASDAQ:CAPR), reported a large exercise of company stock options on October 24,...
The Dow Jones closed higher by around 65 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern aroun...
The Dow Jones closed higher by around 290 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around ...
U.S. stocks turned lower toward the end of trading, with the Dow Jones falling over 200 points on Friday. The Dow traded down 0.70% to 33,432.17 wh...
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group ...
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Friday. The Dow traded up 0.13% to 33,710.74...
News, Short Squeeze, Breakout and More Instantly...
Capricor Therapeutics Inc. Company Name:
CAPR Stock Symbol:
NASDAQ Market:
Capricor Therapeutics Inc. Website:
-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patients- -Improvements Seen in Multiple Cardiac Endpoints Demonstrating Stabilization of Cardiac Function Over 3 Years of Treatment- -Pre-BLA Meeting with FDA...
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- In a release issued under the headline "Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy" on Tuesday, June 25th by Capricor Therapeutics, please note that the words "Pre-BLA Meeting with FDA for Deramiocel" were omitted ...
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has scheduled a Pre...